Evidence map›Paper›PMID 39180099›Full record

ReviewEuropean journal of medical research2024

miR-210 in ischaemic stroke: biomarker potential, challenges and future perspectives.

Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Vivek Sanker, Ismaila Ajayi Yusuf, Temiloluwa Oluwakorede Adefusi, Emmanuel Egbunu, John Ehi Aboje, Oluwatobiloba Oluwatomisin Apampa, Ikponmwosa Jude Ogieuhi and 2 more

Abstract readReview
In one paragraph

Review in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas AderintoDepartment of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. nicholasoluwaseyi6@gmail.com.
Gbolahan OlatunjiDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Emmanuel KokoriDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Vivek SankerDepartment of Neurosurgery, Trivandrum Medical College, Thiruvananthapuram, Kerala, India.
Ismaila Ajayi YusufDepartment of Medicine and Surgery, Obafemi Awolowo University Teaching Hospital, Ife, Nigeria.
Temiloluwa Oluwakorede AdefusiDepartment of Medicine and Surgery, Bowen University Teaching Hospital, Iwo, Nigeria.
Emmanuel EgbunuFederal Medical Centre Bida, Niger, Nigeria.
John Ehi AbojeCollege of Health Sciences, Benue State University, Benue, Nigeria.
Oluwatobiloba Oluwatomisin ApampaDepartment of Medicine and Surgery, Obafemi Awolowo University Teaching Hospital, Ife, Nigeria.
Ikponmwosa Jude OgieuhiSiberian State Medical University, Tomsk, Russia.
Opabode Muntaqim ObasanjoDepartment of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Wireko Andrew AwuahFaculty of Medicine, Sumy State University, Sumy, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischaemic stroke, a leading cause of global morbidity and mortality, necessitates effective biomarkers for enhanced diagnostic and prognostic stratification. MicroRNAs (miRNAs), particularly miR-210, have emerged as promising candidates due to their intricate regulatory roles in cellular responses to hypoxia and neuroprotective effects. This study explores the potential of miR-210 as a biomarker for ischaemic stroke, considering its expression patterns, regulatory functions and diagnostic/prognostic implications. A literature search was conducted on PubMed, Scopus, Google Scholar and Web of Science to identify studies focusing on miR-210 in ischaemic stroke. Inclusion criteria comprised reports on miR-210 expression in ischaemic stroke patients, excluding non-English studies, reviews, commentaries and conference abstracts lacking primary data. Studies investigating miR-210 levels in ischaemic stroke patients revealed significant alterations in expression patterns compared to healthy controls. Diagnostic potential was explored, indicating miR-210's sensitivity and specificity in distinguishing ischaemic stroke from other neurological conditions. Prognostic value was evident through associations with infarct size, functional outcomes and long-term survival. Challenges included variability in miR-210 levels, limited diagnostic specificity, absence of standardised assays and concerns regarding cost-effectiveness and accessibility. While miR-210 holds promise as an ischaemic stroke biomarker, challenges must be addressed for its successful integration into clinical practice. Standardised reference ranges, validation studies in diverse populations and collaborative efforts for assay standardisation are crucial. Despite challenges, miR-210's diagnostic and prognostic potential, particularly in predicting therapeutic responses, suggests a significant role in advancing ischaemic stroke management.

Indexed as

BiomarkersIschemic StrokeMicroRNAsHumansPrognosisBiomarkersMicroRNAsMIRN210 microRNA, humanBiomarkerHypoxiaIschaemic strokeMiR-210

Identifiers

PMID39180099
PMCPMC11342498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.